Keryx Biopharmaceuticals (KERX) stunned the market yesterday after releasing positive phase 3 data for its hyperphosphatemia drug Zerenex. Shares jumped around 75% after the news was released, and investors are still enjoying the newfound optimism surrounding this biotech company. Shares hopped another 40% today, but what caused this additional jump? What should investors watch for going forward? In this video, health care analyst Max Macaluso dives into these questions.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.